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Abstract: Importance: Traditionally cyclophotocoagulation has been reserved as a treatment of last
resort for eyes with advanced stage glaucoma, but increasingly it is offered to eyes with less severe
disease. Endoscopic approaches in particular are utilized in increasing numbers of patients despite
only a small number of publications on its results. Objective: The purpose of this study was to
compare the efficacy and safety of endoscopic and transcleral cyclophotocoagulation (ECP and TCP)
procedures in eyes with refractory glaucomas. Design, Setting, and Participants: A chart review was
performed on consecutive patients who underwent ECP and TCP at a tertiary ophthalmology care
center between January 2000 and December 2010. Cases with fewer than 3 months of follow-up
or that had concurrent pressure reducing procedures were excluded. The main outcome measures
examined were intraocular pressure (IOP), number of glaucoma medications, best corrected visual
acuity (BCVA), additional glaucoma procedure required, and complications. Main Outcomes and
Measures: Forty-two eyes (42 patients) that underwent ECP and forty-four eyes (44 patients) that
underwent TCP were identified. The TCP group had a statistically higher mean age (71.2 ± 16.7
vs. 58.1 ± 22.9 years, respectively), larger proportion of neovascular glaucoma (40.9% vs. 16.7%),
worse initial BCVA (logMAR 2.86 vs. 1.81), and higher preoperative IOP (45.3 vs. 26.6 mmHg)
than the ECP group. At 12 months follow-up, the mean IOP difference between groups was not
statistically significant, although the change in IOP from baseline to 12 months was greater for the
TCP group (p = 0.006). The rates of progression to no light perception (NLP) and phthisis bulbi were
significantly higher amongst TCP eyes than ECP eyes (27.2% vs. 4.8%, p = 0.017, and 20.5% vs. 0%,
p = 0.003, respectively). Of these eyes that progressed, a majority had neovascular glaucoma (NVG).
Corneal decompensation was the most frequent complication following ECP (11.9%). Conclusions and
Relevance: In patients with preoperative BCVA of 20/400 or better, overall complication rates (cystoid
macular edema, exudative retinal detachment, inflammation, cornea decompensation) were higher
after ECP than with TCP. In refractory glaucomas in a real world setting (not a trial), TCP was more
frequently used in ischemic eyes. TCP was associated with a higher rate of progression to phthisis
bulbi and loss of light perception than ECP. However, ECP was associated with a clinically significant
rate of corneal decompensation. These outcomes likely were related to the severity of underlying
ocular diseases found in these eyes.
Keywords: cyclophotocoagulation; endoscopic cyclophotocoagulation; transcleral cyclophotocoagulation;
cycloablation; cyclodestruction
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1. Introduction
Laser cyclophotocoagulation is a surgical procedure that treats the ciliary processes and thereby
reduces aqueous humor production in order to decrease intraocular pressure (IOP). Using a diode laser,
ablation of the ciliary processes can be carried out either as endoscopic cyclophotocoagulation (ECP)
or as transcleral cyclophotocoagulation (TCP). Advantages of cyclophotocoagulation lie in refractory
glaucomas where outflow procedures and medications have been utilized unsuccessfully, and in the
case of TCP, in patients who cannot go to the operating room.
Laser cyclophotocoagulation in the form of TCP has generally been reserved for eyes with limited
visual potential due to significant rates of vision loss and phthisis bulbi reported in the literature [1,2].
However, there are also studies of TCP in eyes with good visual acuity that have not shown these
concerning complication rates [3–7]. For eyes with good vision, it has been suggested that ECP
may be advantageous over TCP because ECP provides a more targeted destruction of the ciliary
epithelium, sparing the ciliary process blood flow [8]. The lower reported incidence of phthisis and
hypotony following ECP may be attributed to the lack of choroidal blood flow disruption. These
factors may make ECP preferable for eyes with neovascular glaucoma (NVG), a disease in which
there is a higher rate of hypotony and phthisis bulbi following TCP as compared to treatment of other
glaucoma types [9]. However, direct comparison of ECP and TCP is limited in the literature because
of differences in patient populations, glaucoma subtype, and disease severity of patients undergoing
ECP and TCP.
In this study, we present a large consecutive case series of all ECP and TCP procedures performed
at a single institution for a variety of glaucomas. The purpose of this study is to compare the outcomes
and complications associated with each procedure. Additionally, we evaluate the two procedures in
eyes with better initial visual acuity (20/400 or better) and in eyes with NVG.
2. Materials and Methods
Medical records of all patients who underwent ECP or TCP between January 2000 and December
2010 at the Jules Stein Eye Institute were retrospectively reviewed. University of California, Los Angeles
Institutional Review Board approval was obtained for this study. This research was adherent to the
tenets of the Declaration of Helsinki. Patients were excluded if postoperative follow-up was shorter
than 3 months or if a concurrent pressure reducing surgery was performed. One eye per patient was
enrolled. If both eyes of a patient had the same type of cyclophotocoagulation procedure (ECP or TCP)
and qualified, the first eye that received the cycloablation procedure was enrolled.
ECP was performed with the EndoOptiks E2 system 810 nm diode laser (Endo Optiks, Inc., Little
Silver, NJ, USA). ECP treatment was delivered by inserting the treatment probe through a temporal
clear corneal paracentesis or through a pars plana sclerotomy. TCP was performed with the IRIS
Oculight 810 nm with G-Probe (Iridex, Inc., Mountain View, CA, USA).
Preoperative data collected included demographic characteristics, systemic diagnoses and
medications, ocular diagnoses, intraocular pressure (IOP), glaucoma medications, best-corrected
visual acuity (BCVA), and previous ocular surgeries. Intraoperative data collected included total
intraoperative energy applied in Joules for TCP, extent of treatment in degrees for ECP, and
intraoperative complications. TCP energy (in Joules) delivered was calculated by multiplying the
number of laser burns by the duration (seconds) and power (Watts). ECP was performed at 25 mJ
on a continuous mode setting; only circumferential extent of treatment was reported in operative
reports. Postoperatively, BCVA, IOP, and number of glaucoma medications were collected at 1 month
(±2 weeks), 3 months (±4 weeks), 6 months (±2 months), 12 months (±2 months), and each
year (±2 months) thereafter. Additionally, post-operative complications, and repeat surgical and
cyclophotocoagulative interventions were recorded throughout the entire follow-up period.
Early complications were defined as those that occurred within one month following surgery,
while late complications were defined as those that developed after 1 month. Hypotony was defined as
an IOP at or below 5 mmHg without phthisis, and phthisis was defined as intraocular disorganization
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regardless of IOP level. Corneal decompensation was defined as persistent stromal edema greater than
3 months duration in a previously clear cornea. Uveitis was defined as persistent anterior chamber
reaction greater than 1 month in duration.
BCVA was modeled as the negative logarithm of the reciprocal of the minimum angle of resolution
(logMAR) for the purposes of statistical analysis. LogMAR values of 2.3, 2.9, 3.2, and 3.5 were assigned
to counting fingers, hand motion, light perception, and no light perception visions, respectively,
according to the grading scheme of the World Glaucoma Association [10].
Outcome measurements included intraocular pressure (IOP), number of glaucoma medications,
best corrected visual acuity (BCVA), additional glaucoma procedure required, and complications.
The Wilcoxon signed rank test was used to compare outcomes within groups. The Wilcoxon rank
sum test, Fisher exact test, and Student t-test were used to compare differences in outcomes between
study groups. Statistical analysis was performed with SAS software version 9.1 (SAS, Inc., Cary, NC,
USA). p-values ≤ 0.05 were considered statistically significant. Mean values were presented with their
standard deviations (±S.D.).
3. Results
A total of 42 eyes of 42 patients treated by ECP and 44 eyes of 44 patients treated by TCP met
inclusion criteria. Mean follow-up times between the two groups were similar (19.4±17.3 months
after ECP and 17.8 ± 18.7 months after TCP). Patients who underwent TCP had different preoperative
characteristics than those who underwent ECP. (Table 1) Patients who underwent TCP were older
(mean age: 71.2 ± 16.7 vs. 58.1 ± 22.9 years, p = 0.003, respectively) and had higher preoperative IOP
(45.3 vs. 26.6 mmHg, p = 0.001). In addition, the TCP group had a greater proportion of neovascular
glaucoma (40.9% vs. 16.7%, p = 0.05), but a smaller proportion of patients that had prior known
glaucoma surgeries (20.5% vs. 92.9%, p = 0.0001).
Table 1. Baseline Characteristics of Subjects.
Subject Characteristics ECP TCP p Value *
Total subjects 42 44
Age in years (Mean ± StdDev) 58.1 ± 22.9 71.2 ± 16.7 0.003 **
Male, No.(%) 28 (66.7) 24 (54.5) 0.28
Right Eye, No.(%) 25 (59.5) 18 (40.9) 0.13
Initial BCVA (logMar) 1.81 2.86 0.0001
Initial NLP eyes, No.(%) 1 (2.4) 22 (50.0) <0.0001
Blood thinner use (%) 20.5 0.31
Systemic comorbidity, No.(%) 27 (64.3) 32 (72.7) 0.49
Type of glaucoma, No. (%) 0.0496
Congenital 8 (19.0) 2 (4.5)
Primary Open Angle 9 (21.4) 6 (13.6)
Secondary Open Angle 5 (11.9) 2 (4.5)
Chronic Angle Closure 3 (7.1) 4 (9.1)
Secondary Angle Closure (traumatic) 2 (4.8) 2 (4.5)
Secondary Angle Closure (nontraumatic) 6 (14.3) 6 (13.6)
Secondary Angle Closure (neovascular) 7 (16.7) 18 (40.9)
Aphakic 1 (2.4)% 3 (6.8)
Other/Nonspecified 1 (2.4) 1 (2.3)
Prior glaucoma surgery, No. (%) 29 (92.9) 9 (20.5) <0.0001
Any prior eye surgery, No.(%) 42 (100) 30 (68.2) <0.0001
Lens status 0.15
Pseudophakic, No.(%) 21 (50.0) 18 (40.9)
Aphakic, No.(%) 11 (26.2) 7 (15.9)
Phakic, No.(%) 10 (23.8) 19 (43.2)
* All p-values were from Fisher exact test unless noted otherwise; ** t test; ECP: endoscopic cyclophotocoagulation,
TCP: transcleral cyclophotocoagulation, BCVA: best corrected visual acuity, POAG: primary open angle glaucoma,
NLP: no light perception, Systemic comorbidities include hypertension, diabetes mellitus, cerebrovascular
accident, cancer.
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Preoperative visual acuity in the TCP group was worse than in the ECP group, and the mean
vision in both groups was poor (logMAR 2.86 vs. 1.81, respectively, p = 0.0001, which is worse than
20/800 for both groups). No light perception (NLP) vision prior to cyclophotocoagulation was more
prevalent in TCP than in ECP patients (50.0% vs. 2.4%, p = 0.0001). Conversely, the ECP group had a
higher proportion of patients with BCVA of 20/400 or better than the TCP group (42.9% vs. 15.9%).
On average, 257.8 ± 70.9◦ of the pars plicata was treated by ECP. ECP was performed via a
clear-cornea approach in 38 eyes and via the pars plana in four eyes. In the TCP group, the mean
treatment time was 1.7 s, the power was 1984 mW, and 21.3 applications were given on average.
Treatment was over 360◦ in all but two cases and the three and nine o’clock positions where posterior
ciliary arteries emerge forward were avoided.
3.1. Intraocular Pressure Control
Intraocular pressure and need for glaucoma medications were significantly reduced in both the
ECP and TCP groups. (Table 2) At the 12 month follow-up, mean IOP was reduced from 26.6± 10.9 mmHg
at baseline to 19.0 ± 9.4 mmHg in the ECP group (p = 0.013) and from 45.3 ± 15.4 at baseline to 22.2 ±
12.7 mmHg in the TCP group (p < 0.0001). The final mean IOP at 12 months of follow-up was similar
between the groups (19.0 [ECP] and 22.2 mmHg [TCP]) despite a large difference in the baseline IOPs
(difference between groups for change in IOP from baseline to 12 months, p = 0.006). The mean number
of glaucoma medications required was reduced from 3.1 to 2.3 in the ECP group (p < 0.001) and from
3.0 to 2.0 in the TCP group (p < 0.001).
Additional glaucoma procedures were performed for inadequate IOP control in 16/42 ECP eyes
(38.1%) and in 16/44 TCP eyes (36.4%). In the ECP group, repeat cyclophotocoagulation was performed
in 6/42 eyes (14.2%) (two had repeat ECP and four eyes received subsequent TCP). A glaucoma
drainage device was placed in 9/42 (21.4%) of the ECP eyes. Of the ECP cohort that required additional
glaucoma surgery, the initial extent of treatment was 276.9 ± 56.2◦ (slightly greater than the average
extent of treatment for the entire group). In the TCP group, seven eyes received a glaucoma drainage
device, one eye underwent trabeculectomy, one had ECP, and seven had repeat TCP. Those TCP
eyes that required further treatment had slightly lower initial treatment energy of 62.2 ± 30.9 Joules
compared to the group average.
3.2. Visual Acuity
The differences between preoperative and 12-month follow-up average BCVA was not significant
in the ECP group (p = 0.57) but mildly significant in the TCP group (p = 0.03) (Table 2). Of the 63 eyes
between both groups with preoperative sight, six eyes progressed to NLP vision. Progression to NLP
was more common in the TCP group, 6/21 eyes (28.5%), than in the ECP group, 2/41 (4.9%) (p = 0.017)
(Table 3) The six eyes that went NLP after TCP had baseline visions of HM (n = 1) to LP (n = 5) and
progressed to NLP vision between postoperative month 1 and year 4. All eyes had NVG: four were
secondary to central retinal vein occlusion, one from diabetic retinopathy, and one due to intraocular
tumor. The two ECP eyes that progressed to NLP had starting visions of 20/200 and CF. The eye
starting with 20/200 vision carried a diagnosis of Stickler’s syndrome and suffered an intraoperative
choroidal hemorrhage during pars plana ECP and progressed to NLP within 1 month of surgery. The
eye with CF vision at baseline had a diagnosis of NVG due to central retinal artery occlusion and
maintained CF vision through the 6 month follow-up but was NLP at the subsequent 12 month time
point, presumably due to progressive ischemia from the artery occlusion.
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Table 2. Intraocular pressure, vision, and medications before and after ECP and TCP as seen in all eyes, neovascular eyes, and eyes with BCVA 20/400 or better.
Total Cohort Neovascular Glaucoma Cohort BCVA≥ 20/400 Cohort
ECP TCP ECP TCP ECP TCP
n Mean p-Value n Mean p-Value n Mean p-Value n Mean p-Value n Mean p-Value n Mean p-Value
Follow up (mo) 19.5 17.8 13.6 22.8 18.6 17.4
Initial BCVA 42 1.81 44 2.86 0.0001 * 7 2.99 18 3.25 0.13 * 18 0.62 7 0.51 p = 0.39 *
12 mo. BCVA 24 1.62 23 2.99 3 3.1 11 3.39 11 0.68 3 0.42
Change in BCVA 24 −0.03 0.57 23 0.09 0.03 3 0.4 1 11 0.19 0.06 11 0.09 0.98 3 −0.1 0.5
Preoperative IOP (mmHg) 42 26.6 44 45.3 7 32.1 18 47.8 18 21.8 7 33.4
12 month IOP (mmHg) 23 18.9 23 22.2 3 29.3 11 14.6 10 20.1 3 27.0
Change in IOP (mmHg) 23 −7.7 0.01 23 −22.6 <0.0001 3 −3.0 1 11 −31.8 0.002 10 −1.8 0.54 3 −9.7 0.25
Initial Medications 3.1 3 3.1 2.8 3.5 3.1
Final Medications 2.3 2 2.1 1.3 2.3 3.6
Repeat Procedure or 42 16 (38.1) 44 16 (36.4) 7 1 (14.3) 18 5 (27.8) 18 7 (38.9) 7 4 (57.1)Surgery, No. (%)
IOP: intra-ocular pressure, ECP: endoscopic cyclophotocoagulation, TCP: transcleral cyclophotocoagulation, BCVA: best corrected visual acuity. All p-values were from Wilcoxn signed
rank test unless otherwise noted in order to compare pre-operative and 12-month outcomes within the ECP or TCP cohorts. * Wilcoxon rank sum test was used to initial BCVA between
ECP and TCP in all groups.
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Table 3. Complications of ECP and TCP as seen in all eyes, neovascular eyes, and eyes with BCVA
20/400 or better.
Total Cohort NVG Cohort BCVA >20/400 Cohort
ECP TCP p-Value * ECP TCP p-Value * ECP TCP p-Value *
Sample Size 42 44 7 18 18 7
Acute Adverse Event
(<1month), No.
Fibrinoid reaction 1 0 0.49 0 0 n/a 1 0 1.0
Corneal
decompensation 1 0 0.5 0 0 n/a 0 0 n/a
Post operative cylinder 1 0 0.49 0 0 n/a 1 0 1.0
Persistent AC reaction 2 0 0.24 0 0 n/a 0 0 n/a
Epitheliopathy 1 0 0.49 1 0 1.0 0 0 n/a
Choroidal hemorrhage 1 1 1.0 0 0 n/a 1 0 1.0
Vitritis 1 0 0.49 0 0 n/a 0 0 n/a
Macular Edema 2 0 0.24 0 0 n/a 2 1 1.0
Retinal Detachment 1 1 1.0 0 0 n/a 0 0 n/a
Hyphema 0 1 1.0 0 1 1.0 0 0 n/a
Persistent Lid Edema 0 1 1.0 0 1 1.0 0 0 n/a
Malignant glaucoma 0 1 1.0 0 1 1.0 0 0 n/a
Late Adverse Event
(>1 month), No.
Corneal
decompensation 4 1 0.20 0 1 1.0 2 0 1.0
Phthisis 0 9 0.003 0 7 0.13 0 0 n/a
Hypotony 2 4 1.0 0 2 1.0 2 0 1.0
Uveitis 1 1 1.0 0 0 1.0 1 1 0.49
Progression to NLP 2 6 0.017 1 4 0.30 1 0 1.0
* All p-values were from Fisher exact test. ECP: endoscopic cyclophotocoagulation; TCP: transcleral
cyclophotocoagulation; AC: anterior chamber; RD: retinal detachment. NVG: neovascular glaucoma; CME: cystoid
macular edema; NLP: no light perception.
3.3. Complications
Intraocular complications were reported rarely. One eye, as noted above, suffered an acute
choroidal hemorrhage during ECP via a pars plana approach. Early and late postoperative
complications are summarized in Table 3. The rate of early postoperative complications between ECP
and TCP were similar. Retinal detachment developed in one eye of each group; an exudative retinal
detachment was seen after ECP and a rhegmatogenous retinal detachment developed in one TCP eye.
Late complications were encountered more commonly in the TCP group. Phthisis bulbi developed in
nine TCP eyes (20.5%) compared to zero ECP eyes (p = 0.003). However, corneal decompensation in
previously clear corneas was more frequent in ECP. It was seen in five ECP eyes (11.4%) and in one
TCP eye (2.5%). Sympathetic ophthalmia was not encountered.
3.4. Subgroup Analysis: Neovascular Glaucoma
There were 25 eyes that had NVG; seven eyes underwent ECP and 18 eyes underwent TCP. Initial
BCVA was generally poor in both ECP and TCP groups (logMAR 2.99, 3.25, respectively, p = 0.13,
[2.9 = HM]). BCVA at 12 months follow-up worsened in both groups, p = 0.57 for the change in vision
for the ECP group and p = 0.03 for the TCP group. Vision was NLP prior to cyclophotocoagulation
procedure in one eye that underwent ECP and in 10 eyes that underwent TCP. Loss of preoperative
vision to NLP occurred in one of six eyes (16.7%) in the ECP group and in four of eight eyes (50%) in
the TCP group (p = 0.30).
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Mean preoperative IOP of the NVG eyes was greater in the TCP group than in the ECP group
(47.8 mmHg, 32.1 mmHg, respectively, p = 0.02). IOP at 12 months follow-up was lower in the TCP
than in the ECP group (14.6 mmHg, 29.3 mmHg, respectively, p = 0.05) (Table 2).
Hypotony at final follow-up was seen in six eyes (33.3%) with NVG in the TCP group versus
none in the ECP group. Progression to phthisis occurred in 7/18 eyes (37.8%) treated with TCP but in
none in the ECP group (p = 0.13). There were no other significant differences in either early or late
complications between the two groups (Table 3).
3.5. Subgroup Analysis: Patients with BCVA 20/400 or Better
There were 25 eyes with BCVA of 20/400 or better. ECP was performed on 18 and TCP on seven
of these better sighted eyes. There were no significant differences between the two groups with regards
to preoperative and postoperative BCVA or change of BCVA after cyclophotocoagulation procedure
at 12 months follow-up. A loss of two or more lines of vision occurred in 7/18 (38.8%) eyes in the
ECP group (with one eye losing vision to NLP) and in one out of seven eyes (14.3%) in the TCP group,
however a comparison failed to reach statistical significance. The eye that lost all vision in the ECP
group was the previously mentioned Stickler syndrome eye with intraoperative choroidal hemorrhage.
The reduction of IOP failed to reach significance in either group (ECP p = 0.54 and TCP p = 0.25) likely
due to small numbers (Table 2). There was a significantly higher rate of early and late postoperative
complications seen in the ECP group, such as cystoid macular edema, exudative retinal detachment,
choroidal hemorrhage, inflammation, and corneal decompensation (Table 3). However, none of these
reached statistical significance due to the small sample size of the TCP group.
4. Discussion
In this retrospective cases series of ECP and TCP, it is evident that both procedures may achieve
significant pressure reduction. Patients who underwent TCP were older with worse preoperative
vision and higher IOP, and more eyes had NVG than in the ECP cohort. The different preoperative
characteristics of patients who underwent ECP and TCP reflect the traditional practice of using TCP
on eyes with refractory glaucomas with little visual potential. This treatment bias stems from an
association with vision loss in a substantial number of eyes treated by cyclophotocoagulation of the
ciliary processes [1,2,11]. In the subgroup analysis of eyes with NVG, TCP was observed to have a
high rate of postoperative complications, including phthisis bulbi and loss of light perception. In the
small number of eyes with BCVA of 20/400 of better, ECP was observed to have a high rate of corneal
decompensation and overall postoperative complications. The number of eyes and difference in loss
to follow-up in the subgroup analyses limit the ability to draw strong conclusions comparing the two
procedures in these subgroups.
The effectiveness of IOP reduction with TCP and ECP in our series is consistent with the literature.
An IOP reduction of ≥30% from baseline has been reported in 12.3–66% of TCP procedures [11]. In our
series, 63.6% of TCP cases and 57.1% of ECP cases showed at least a 30% reduction in IOP. Also, in our
series a final IOP of 5-21 mmHg was seen in 34.1% of TCP and 71.4% of ECP procedures, whereas
in the literature at 1 year this final range of IOP was seen in 54.0–92.7% of TCP and 17–94% ECP
cases, according to one review [11]. Reasons for such varying rates of success amongst studies include
different patient populations and different treatment protocols. The amount of energy delivered has
been correlated to treatment success in some studies [12–14], although not in all [4,15,16]. Our total
average energy administered of 71.8 J fell within the range of previous TCP reports from 46.6 to
155.2 J [11]. Other factors found to influence treatment results include preoperative IOP level [4],
age [17–19], glaucoma type [17–19], history of previous surgery [18–20], and pigmentation [13,21,22].
Complications in our groups of TCP and ECP are similar to those seen in the literature, except
for a greater incidence of corneal decompensation than previously reported for ECP. The literature
reports a low incidence of serious complications following ECP, although it has been noted that ECP
complications are higher in eyes with NVG and refractory glaucomas [23–27]. In our ECP group,
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we encountered fibrinoid reactions, retinal detachment, choroidal hemorrhage, vitritis, cystoid macular
edema, corneal decompensation, and progression to NLP vision. Corneal decompensation requiring
further treatment (penetrating keratoplasty or keratoprosthesis) was the most frequent adverse event
in the ECP group, occurring in five of 42 eyes (11.9%); one case developed decompensation acutely
and four progressed to decompensation after 1 month. Francis et al. similarly reported a 12% rate
of corneal or corneal graft edema in 25 eyes following ECP [24]. Phthisis bulbi was exclusively seen
in eyes that underwent TCP in our study, although it has been reported in the literature following
ECP [25,26]. Loss of vision was experienced by eyes in both treatment groups, but was more frequent
in the TCP group. Progression to NLP vision was significantly greater in the TCP group, which overall
contained eyes with more advanced disease, and five of the six eyes that ended up NLP were LP prior
to treatment. Of the two ECP eyes that progressed to NLP, ECP may or may not have contributed to
the ultimate causes of NLP, which were a choroidal hemorrhage in an eye with Stickler’s syndrome
and ischemia in an eye with NVG secondary to central retinal artery occlusion.
A series by Ramli et al. demonstrated that eyes with NVG are at much higher risk for hypotony
after TCP than eyes with other forms of glaucoma [9]. We evaluated our subset of eyes with NVG
and found that 11.1% of cases with NVG progressed to hypotony after TCP. A total of 38.8% (7/18)
became phthisical. Our average energy level, 75.4 J (median 69 J, and range 5–185 J) was similar to
the 83.3 ± 31.7 J used in Ramli’s study. Of the sighted eyes undergoing TCP, half progressed to NLP.
Interestingly, of the seven cases of NVG treated by ECP none progressed to phthisis or hypotony,
but one did progress to NLP vision. The follow up in the NVG ECP group was 9.2 months shorter than
in the NVG TCP group, and longer follow-up might have allowed for the development of phthisis
or hypotony. Animal studies have demonstrated less disorganization of the ciliary architecture and
vasculature following ECP, as well as partial reperfusion of the processes within 1 month of ECP that
was not seen after TCP [8,28], The less destructive nature of ECP may be of benefit in NVG eyes that
have a compromised vasculature. However, there may not be a totally safe procedure for vasculopathic
eyes. Even after tube shunts there is a high rate of progression to NLP in NVG eyes of 24% to 31%,
and a tube implantation does not affect the eye’s vasculature [29,30]. We observed that ECP was better
tolerated in our small group of NVG eyes , however, it is possible that eyes with less severe ischemia
were selected for ECP treatment in our cohort. A larger sample is required to confirm this observation.
Additionally, given reports using ECP and TCP as a primary treatment of glaucoma and in eyes
with good visual potential [3–6,31], we examined eyes with 20/400 or better vision to see if either
treatment had a detrimental effect on vision, IOP, and complications. In a retrospective review by
Rotchford et al. of ECP in eyes with an initial median BCVA of 20/30, a loss of two lines of BCVA
was seen in 30% of eyes. The authors could not attribute the loss of vision to the procedure rather
than to the underlying glaucoma given the mean follow up of 5 years. Similar rates of vision loss
over 5 years have been seen secondary to glaucoma progression in studies utilizing other types of
glaucoma surgery [32,33]. In our subgroup of eyes with 20/400 or better vision, 38.8% of ECP eyes
and 14.3% of TCP eyes lost >2 lines of vision. Progression to NLP occurred in one ECP eye but no
TCP eyes. In refractory glaucomas undergoing ECP, reported complication rates are higher than rates
seen in milder glaucomas treated by ECP: vision loss of at least two lines has been reported as high as
6% [34], hypotony in 8% [27], and phthisis in up to 3% of cases [25]. Although the number of eyes in
this study’s subgroup is very small, these rates of vision loss at 1 year may call for caution in treating
eyes with refractory glaucomas and better vision.
This study is limited by its retrospective nature. There is an acknowledged bias in treatment
recommendations, as the more severely diseased eyes tended to undergo TCP rather than ECP.
However, the entire group of eyes falls into the severe stage of glaucoma or even end stage glaucoma.
A prospective study can address these deficiencies, and be appropriately powered to detect a difference
in IOP outcomes between the two procedures. Additionally, the rate of complications is likely
underestimated in this study, both due to the retrospective design and the clarity of media of some
of the included eyes, which may have limited complete clinical evaluation of the posterior segment.
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Complications like cystoid macular edema (quoted to occur in up to 4.3%) and fibrin exudates (7.3%)
are difficult to detect in eyes with cloudy media [25]. However, rates of vision loss would still be
accurately reported even with the retrospective design. Lastly, the subset analyses of NVG and eyes
with better vision were small limiting generalizability. Strengths include a relatively large sample size
and inclusion of all types of refractory glaucomas, which allows for greater generalizability to what
may happen in clinical practice.
5. Conclusions
In conclusion, each method of cyclophotocoagulation demonstrates an ability to significantly
reduce IOP in a variety of advanced glaucomas. The ECP group had a higher corneal decompensation
rate but less progression to phthisis and NLP than the TCP group, which conversely had a higher
rate of final NLP vision and phthisis. Sympathetic ophthalmia was seen in neither group. This data,
although limited due to its retrospective collection bias, may suggest that further investigation of
the rate of phthisis bulbi between ECP and TCP is warranted in eyes with neovascular glaucoma.
Lastly, these data may suggest caution using ECP for treatment of refractory glaucomas in eyes with
usable vision and low corneal endothelial cell counts, as the rate of corneal decompensation here was
clinically significant.
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